Showing 2491-2500 of 3050 results for "".
- Sciton Announces New Leadership Teamhttps://practicaldermatology.com/news/sciton-announces-new-leadership-team/2457777/Sciton has an all new leadership team. The new Sciton leaders are: Aaron Burton, Chief Operating Officer Todd Sternbach, Vice President of Strategic Sales Initiatives David Percival, Vice President / General Manager of Sciton International Lacee Jacobson Na
- AAD Launches Campaign to Support Skin Self Examshttps://practicaldermatology.com/news/aad-launches-campaign-to-support-skin-self-exams/2457782/In recognition of Skin Cancer Awareness Month in May and Melanoma Monday® on May 7, the American Academy of Dermatology is encouraging the public to be a “Skin Can
- Acne Survey at Twins Convention Affirms Genetic Linkhttps://practicaldermatology.com/news/acne-survey-at-twins-convention-affirms-genetic-link/2457789/A survey of identical and fraternal twin pairs at the Twins Days Festival in Twinsburg, OH, and published in the April issue of the Journal of Drugs in Dermatology, shows acne may be primarily caused by genetics.
- Parents Just Don't Understand Risks of Sun Exposure in Springhttps://practicaldermatology.com/news/parents-just-dont-understand-risks-of-sun-exposure-in-spring/2457791/Slightly more than 90 percent of parents underestimate the sun’s strength in spring and as a result, don’t adequately protect their children, according to a survey by parent magazine Kinderzeit.org. Specifically, 90.6 percent of parents polled tend to forget to apply sun
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- Melanoma Reduces Alzheimer's Risk: Studyhttps://practicaldermatology.com/news/melanoma-reduces-alzheimers-risk-study/2457794/Individuals diagnosed with malignant melanoma may have a reduced risk of developing Alzheimer's disease. New findings, recently published online in
- Saudi Arabia Welcomes Scalisi Skin Carehttps://practicaldermatology.com/news/saudi-arabia-welcomes-scalisi-skin-care/2457799/Select doctors’ offices and medical clinics across Saudi Arabia now carry the Scalisi collection. This adds to their existing distribution in spas and medispas in the US, Wynn and Encore Resorts in both Las Vegas, and Macau, China, and online on QVC.com, Amazon.com, and
- Study: Derms More Likely than PAs to Catch Early Skin Cancerhttps://practicaldermatology.com/news/study-derms-more-likely-than-pas-to-catch-early-skin-cancer/2457800/Physician assistants may be more likely than dermatologists to perform unnecessary skin biopsies to check for cancer and are less likely to accurately diagnose early stage skin cancers, according to new research conducted by the University of Pittsbur
- Cutera: 20 Years, 20 Productshttps://practicaldermatology.com/news/cutera-20-years-20-products/2457802/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20
- Using Anti-PD-1 Therapy Pre-Surgery in Melanoma Patients Can Identify Those Most Likely to Benefithttps://practicaldermatology.com/news/using-anti-pd-1-therapy-pre-surgery-in-melanoma-patients-can-identify-those-most-likely-to-benefit/2457806/Shifting use of anti-PD-1 drugs to before surgery may provide clues about which patients will benefit and which may be at increased risk for recurrence, according to new research out of the Abramson Cancer Center of the University of Pennsylvania.